Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Axonics Inc
(NQ:
AXNX
)
68.95
+0.02 (+0.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axonics Inc
< Previous
1
2
3
4
5
6
7
Next >
Axonics® Announces First Patient Implants in Canada With New Recharge-Free Sacral Neuromodulation System
September 08, 2022
From
Axonics, Inc.
Via
Business Wire
Axonics® to Participate in September Investor Conferences
August 18, 2022
From
Axonics, Inc.
Via
Business Wire
Axonics® Expands Sacral Neuromodulation Intellectual Property Portfolio
August 17, 2022
From
Axonics, Inc.
Via
Business Wire
What 9 Analyst Ratings Have To Say About Axonics
August 02, 2022
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings:
Via
Benzinga
Analyst Ratings for Axonics
May 06, 2022
Within the last quarter, Axonics (NASDAQ:AXNX) has observed the following analyst ratings:
Via
Benzinga
Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriter’s Option to Purchase Additional Stock
August 05, 2022
From
Axonics, Inc.
Via
Business Wire
Axonics® Announces Pricing of Public Offering of Common Stock
August 02, 2022
From
Axonics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
August 02, 2022
Gainers Applied DNA Sciences (NASDAQ:APDN) stock rose 90.0% to $5.32 during Tuesday's after-market session. At the close, Applied DNA Sciences's trading volume reached 28.8 million shares. This is...
Via
Benzinga
Axonics® Announces Proposed Public Offering of Common Stock
August 02, 2022
From
Axonics, Inc.
Via
Business Wire
Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance
August 02, 2022
Via
Benzinga
Morgan Stanley Maintains Overweight Rating for Axonics: Here's What You Need To Know
August 02, 2022
Morgan Stanley has decided to maintain its Overweight rating of Axonics (NASDAQ:AXNX) and raise its price target from $73.00 to $80.00. Shares of Axonics are trading up 5.7% over the last 24 hours, at...
Via
Benzinga
Recap: Axonics Q2 Earnings
August 01, 2022
Axonics (NASDAQ:AXNX) reported its Q2 earnings results on Monday, August 1, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Axonics beat estimated earnings by...
Via
Benzinga
Axonics® Reports Second Quarter 2022 Financial Results
August 01, 2022
From
Axonics, Inc.
Via
Business Wire
Axonics® to Report Second Quarter 2022 Financial Results on August 1
July 11, 2022
From
Axonics, Inc.
Via
Business Wire
Earnings Scheduled For August 1, 2022
August 01, 2022
Companies Reporting Before The Bell • Bon Natural Life (NASDAQ:BON) is projected to report earnings for its first quarter.
Via
Benzinga
Axonics® Files PMA Supplement with FDA for Fourth Generation Rechargeable Neurostimulator
May 31, 2022
From
Axonics, Inc.
Via
Business Wire
Axonics® Reports First Quarter 2022 Financial Results
May 05, 2022
From
Axonics, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
May 05, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Axonics® to Participate in BofA Securities 2022 Healthcare Conference
April 26, 2022
From
Axonics, Inc.
Via
Business Wire
Axonics® Announces Comprehensive Launch of the Axonics F15™ Recharge-Free Sacral Neuromodulation System
April 19, 2022
From
Axonics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
April 18, 2022
Gainers Rockwell Medical (NASDAQ:RMTI) stock rose 9.2% to $0.4 during Monday's after-market session. The company's market cap stands at $37.5 million.
Via
Benzinga
Axonics® to Report First Quarter 2022 Financial Results on May 5
April 14, 2022
From
Axonics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
April 06, 2022
Upgrades
Via
Benzinga
Axonics® Launches Direct to Consumer Television Advertising Campaign
April 04, 2022
From
Axonics, Inc.
Via
Business Wire
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
March 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative...
Via
Benzinga
FDA Approves Axonics' Recharge-Free Sacral Neuromodulation System
March 08, 2022
The FDA has approved Axonics Inc's (NASDAQ: AXNX) recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS). The Axonics F15 recharge-free...
Via
Benzinga
A Peek Into The Markets: US Stock Futures Gain Following Monday's Sell-Off
March 08, 2022
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Dow Jones tumbled around 800 points in the previous session. Investors are awaiting earnings...
Via
Benzinga
5 Stocks To Watch - Tuesday, Mar. 8
March 08, 2022
Some of the stocks that may grab investor focus today.
Via
Talk Markets
5 Stocks To Watch For March 8, 2022
March 08, 2022
Some of the stocks that may grab investor focus today are: Wall Street expects Dick's Sporting Goods, Inc. (NYSE: DKS) to report quarterly earnings at $3.43 per share on...
Via
Benzinga
Analyst Ratings For Axonics
February 25, 2022
Axonics (NASDAQ:AXNX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.